TGFB1 and neoplasm: also constructed a bispecific antibody (called BiTP) against TGF-β and human PD-L1 and found that BiTP retained the binding affinity and biological activity of the parent antibody, and it had strong anti-tumor activity against the parent antibody in triple-negative breast cancer (TNBC) (133).